Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 1, 2012, Pages 83-89

  Goldhoff, Patricia ^a   Clarke, Jennifer ^a   Smirnov, Ivan ^a   Berger, Mitchel S ^a   Prados, Michael D ^a   James, C David ^a   Perry, Arie ^a   Phillips, Joanna J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fluorescence in situ hybridization; Glioblastoma; Immunohistochemistry; Patient stratification; RB1; The Cancer Genome Atlas (TCGA)

Indexed keywords

RETINOBLASTOMA BINDING PROTEIN 1;

ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BRAIN NEOPLASMS; GENETIC ASSOCIATION STUDIES; GLIOBLASTOMA; HUMANS; NEURONS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN; STEM CELLS;

EID: 84655161980     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31823fe8f1     Document Type: Article

References (32)

1. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004;101:2293-99 (Pubitemid 39458686)
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96 (Pubitemid 40349501)
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
4. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90 (Pubitemid 47574858)
5. Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009;4:e7752
6. He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833-36
7. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-58
8. Ichimura K, Schmidt EE, Goike HM, et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72 (Pubitemid 26329093)
9. Chow LM, Endersby R, Zhu X, et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011;19:305-16
10. Biernat W, Tohma Y, Yonekawa Y, et al. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 1997;94:303-9 (Pubitemid 27450108)
11. The Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-68
12. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38
13. Lohmann DR, Brandt B, Hopping W, et al. The spectrum of RB1 germline mutations in hereditary retinoblastoma. Am J Hum Genet 1996;58: 940-49 (Pubitemid 26115165)
14. Kim YH, Lachuer J, Mittelbronn M, et al. Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol 2011;21:645-51
15. Nakamura M, Konishi N, Tsunoda S, et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997;80:242-49 (Pubitemid 27282318)
16. Lusis EA, Chicoine MR, Perry A. High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol 2005;73:219-23 (Pubitemid 40974017)
17. Perry A, Nobori T, Ru N, et al. Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 1997;56:999-1008 (Pubitemid 27386129)
18. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98-110
19. Mancini MA, Shan B, Nickerson JA, et al. The retinoblastoma gene product is a cell cycleYdependent, nuclear matrix-associated protein. Proc Natl Acad Sci U S A 1994;91:418-22
20. Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36: 714-21 (Pubitemid 24337629)
21. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73 (Pubitemid 43357943)
22. Mischel PS, Shai R, Shi T, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003;22: 2361-73 (Pubitemid 36566791)
23. James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988;48:5546-51
24. Ransom DT, Ritland SR, Moertel CA, et al. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer 1992;5: 357-74 (Pubitemid 23011206)
25. Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-53 (Pubitemid 26010393)
26. Burns KL, Ueki K, Jhung SL, et al. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998;57:122-30 (Pubitemid 28084274)
27. Kim H, Huang W, Jiang X, et al. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A 2010;107:2183-88
28. Nakamura M, Yonekawa Y, Kleihues P, et al. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001;81:77-82 (Pubitemid 32108641)
29. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A 1990;87:2775-79
30. Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-23
31. Backlund LM, Nilsson BR, Goike HM, et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 2003;9:4151-58 (Pubitemid 37204033)
32. Backlund LM, Nilsson BR, Liu L, et al. Mutations in Rb1 pathwayY related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 2005;93:124-30 (Pubitemid 41076260)